Similarly, in preclinical studies, lapatinib was effective against breast cancer with resistance to trastuzumab [31] whereas, lapatinib added to capecitabine provided superior efficacy compar1ed to capecitabine alone in women with HER2-positive, MBC progressing after prior trastuzumab-based therapy [32]. Here, ERBB2 is linked to breast carcinoma.